ASX Announcement | 26th October 2020
Noxopharm Limited (ASX:NOX)

First Two Cohorts Enrolled in NOXCOVID Study

Sydney 26 October 2020: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) provides an update on its NOXCOVID-1 study.

NOXCOVID-1 is a Phase 1b study looking at the potential use of Veyonda® in blocking cytokine release syndrome ('cytokine storm'), a phenomenon believed responsible for the rapid deterioration of many COVID-19 patients from a situation requiring supplementary oxygen in an emergency situation to requiring intensive care and mechanical ventilation. For safety, the dosage of Veyonda® is being increased gradually from 400 mg up to 1800 mg. The first two dosage cohorts (400mg and 600 mg) have been filled, with a safety steering committee review after 14 days of treatment, planned for early-November. With acceptable patient safety, the next two cohorts (800 mg and 1200 mg) will be enrolled. The study then will expand using the targeted Veyonda® dosage of 1800 mg.

Graham Kelly, Noxopharm CEO and Managing Director, said, "The precarious position of many of these patients, plus not having the benefit of knowing which patients are at risk of progressing, requires everyone to tread cautiously. Hence, we have started with dosages well below where we expect to see any clinical benefit. In the cancer setting, 1200 mg is what we regard as a minimum therapeutic dose. However, cancer is a chronic disease, and we anticipate that in the COVID-19 setting we may have to go up to 1800 mg to address a hyper-acute situation such as a cytokine storm."

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-

About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com

Investor & Corporate enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries
Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.